Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Strosberg, Jonathan, Mizuno, Nobumasa, Doi, Toshihiko, Grande, Enrique, Delord, Jean-Pierre, Shapira-Frommer, Ronnie, Bergsland, Emily, Shah, Manisha, Fakih, Marwan, Takahashi, Shunji, Piha-Paul, Sarina A, O'Neil, Bert, Thomas, Sajeve, Lolkema, Martijn P, Chen, Menghui, Ibrahim, Nageatte, Norwood, Kevin, Hadoux, Julien
Published in Clinical cancer research (01.05.2020)
Published in Clinical cancer research (01.05.2020)
Get full text
Journal Article
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Starodub, Alexander N, Ocean, Allyson J, Shah, Manish A, Guarino, Michael J, Picozzi, Jr, Vincent J, Vahdat, Linda T, Thomas, Sajeve S, Govindan, Serengulam V, Maliakal, Pius P, Wegener, William A, Hamburger, Steven A, Sharkey, Robert M, Goldenberg, David M
Published in Clinical cancer research (01.09.2015)
Published in Clinical cancer research (01.09.2015)
Get full text
Journal Article
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Weber, Jeffrey S, Carlino, Matteo S, Khattak, Adnan, Meniawy, Tarek, Ansstas, George, Taylor, Matthew H, Kim, Kevin B, McKean, Meredith, Long, Georgina V, Sullivan, Ryan J, Faries, Mark, Tran, Thuy T, Cowey, C Lance, Pecora, Andrew, Shaheen, Montaser, Segar, Jennifer, Medina, Theresa, Atkinson, Victoria, Gibney, Geoffrey T, Luke, Jason J, Thomas, Sajeve, Buchbinder, Elizabeth I, Healy, Jane A, Huang, Mo, Morrissey, Manju, Feldman, Igor, Sehgal, Vasudha, Robert-Tissot, Celine, Hou, Peijie, Zhu, Lili, Brown, Michelle, Aanur, Praveen, Meehan, Robert S, Zaks, Tal
Published in The Lancet (British edition) (17.02.2024)
Published in The Lancet (British edition) (17.02.2024)
Get full text
Journal Article
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Chesney, Jason, Lewis, Karl D, Kluger, Harriet, Hamid, Omid, Whitman, Eric, Thomas, Sajeve, Wermke, Martin, Cusnir, Mike, Domingo-Musibay, Evidio, Phan, Giao Q, Kirkwood, John M, Hassel, Jessica C, Orloff, Marlana, Larkin, James, Weber, Jeffrey, Furness, Andrew J S, Khushalani, Nikhil I, Medina, Theresa, Egger, Michael E, Graf Finckenstein, Friedrich, Jagasia, Madan, Hari, Parameswaran, Sulur, Giri, Shi, Wen, Wu, Xiao, Sarnaik, Amod
Published in Journal for immunotherapy of cancer (01.12.2022)
Published in Journal for immunotherapy of cancer (01.12.2022)
Get full text
Journal Article
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
Hamid, Omid, Lewis, Karl D, Weise, Amy, McKean, Meredith, Papadopoulos, Kyriakos P, Crown, John, Kim, Tae Min, Lee, Dae Ho, Thomas, Sajeve S, Mehnert, Janice, Kaczmar, John, Lakhani, Nehal J, Kim, Kevin B, Middleton, Mark R, Rabinowits, Guilherme, Spira, Alexander I, Yushak, Melinda, Mehmi, Inderjit, Fang, Fang, Chen, Shuquan, Mani, Jayakumar, Jankovic, Vladimir, Wang, Fang, Fiaschi, Nathalie, Brennan, Laura, Paccaly, Anne, Masinde, Sheila, Salvati, Mark, Fury, Matthew G, Kroog, Glenn, Lowy, Israel, Gullo, Giuseppe
Published in Journal of clinical oncology (20.08.2024)
Published in Journal of clinical oncology (20.08.2024)
Get full text
Journal Article
771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors
Diab, Adi, El-Khoueiry, Anthony, Abdel-Wahab, Reham, Thomas, Sajeve, Hall, Evan, Wu, Kaida, Maciejewski, Benjamin S, Mehta, Naveen K, Liu, Laura, Michaelson, Jennifer S, Jones, Jeffrey A, Sweis, Randy
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors
To, Minh D, Merchant, Rosemina, Atkinson, Victoria, Bedard, Philippe, Brenner, Warren, Coello, Melissa, Antras, Jesus Fuentes, Galligan, Carole, Lemech, Charlotte, Lloyd, Peter, Karanam, Sudhir Madduri, Margolin, Kim, Mathew, Matthen, Prawira, Amy, Thomas, Sajeve, Twardowski, Przemyslaw, Yavari, Arash, Merchant, Fahar
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Sarnaik, Amod A, Hamid, Omid, Khushalani, Nikhil I, Lewis, Karl D, Medina, Theresa, Kluger, Harriet M, Thomas, Sajeve S, Domingo-Musibay, Evidio, Pavlick, Anna C, Whitman, Eric D, Martin-Algarra, Salvador, Corrie, Pippa, Curti, Brendan D, Oláh, Judit, Lutzky, Jose, Weber, Jeffrey S, Larkin, James M G, Shi, Wen, Takamura, Toshimi, Jagasia, Madan, Qin, Harry, Wu, Xiao, Chartier, Cecile, Graf Finckenstein, Friedrich, Fardis, Maria, Kirkwood, John M, Chesney, Jason A
Published in Journal of clinical oncology (20.08.2021)
Published in Journal of clinical oncology (20.08.2021)
Get full text
Journal Article
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
Olson, Daniel J, Larkin, James, Hong, Young, Thomas, Sajeve, Martin-Liberal, Juan, Furness, Andrew JS, Terheyden, Patrick, In, Gino K, Poklepovic, Andrew S, Samhouri, Yazan, Lammers, Philip, Atkinson, Victoria, Nguyen, Ryan H, Peretz, Idit, Butler, Marcus, Finckenstein, Friedrich Graf, Chou, Jeffrey, Wu, Xiao, Sulur, Giri, Shi, Wen, Haanen, John B
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study
Medina, Theresa, Chesney, Jason A, Whitman, Eric, Kluger, Harriet, Thomas, Sajeve, Sarnaik, Amod A, Kirkwood, John M, Larkin, James, Weber, Jeffrey, Hamid, Omid, Wermke, Martin, Finckenstein, Friedrich Graf, Chou, Jeffrey, Gastman, Brian, Sulur, Giri, Wu, Xiao, Shi, Wen, Domingo-Musibay, Evidio
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
Amin, Asim, Lawson, David H., Salama, April K.S., Koon, Henry B., Guthrie, Troy, Thomas, Sajeve S., O’Day, Steven J., Shaheen, Montaser F., Zhang, Bin, Francis, Stephen, Hodi, F. Stephen
Published in Journal for immunotherapy of cancer (16.08.2016)
Published in Journal for immunotherapy of cancer (16.08.2016)
Get full text
Journal Article
544 DELTA-1: A global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma
Gastman, Brian, Hamid, Omid, Corrie, Pippa, Gibney, Geoffrey, Daniels, Gregory, Chmielowski, Bartosz, Thomas, Sajeve, Domingo-Musibay, Evidio, Lawrence, Donald, Jiang, Yizhou, Kennedy, Audrey, Aycock, Jeff, Alvarez-Rodriguez, Ruben, Robbins, Paul, Gall, John Le, Roberts, Zachary, Hawkins, Robert, Sarnaik, Amod
Published in Journal for immunotherapy of cancer (01.11.2021)
Published in Journal for immunotherapy of cancer (01.11.2021)
Get full text
Journal Article
P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update
Sarnaik, Amod, Khushalani, Nikhil, Chesney, Jason, Kluger, Harriet, Curti, Brendan, Lewis, Karl, Medina, Theresa, Thomas, Sajeve, Pavlick, Anna, Whitman, Eric, Algarra, Salvador, Corrie, Pippa, Hamid, Omid, Lutzky, Jose, Olah, Judit, Weber, Jeffrey, Larkin, James, Shi, Wen, DiTrapani, Kelly, Qin, Harry, Mirgoli, Mariam, Wu, Renee, Takamura, Toshimi, Fardis, Maria, Kirkwood, John
Published in Journal for immunotherapy of cancer (01.04.2020)
Published in Journal for immunotherapy of cancer (01.04.2020)
Get full text
Journal Article
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma
Olson, Daniel, Hong, Young, Thomas, Sajeve Samuel, Martin-Liberal, Juan, Graf Finckenstein, Friedrich, Wu, Renee Xiao, Sulur, Giri, Shi, Wen, Larkin, James
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Phase 2 Study of Intratumoral Vidutolimod With Intravenous Cemiplimab in Patients With Locally Advanced or Metastatic Merkel Cell Carcinoma (CMP-001- 009)
Bhatia, Shailender, Hyngstrom, John R., Ikeguchi, Alexandra, Thomas, Sajeve S., Silk, Ann W., Bobilev, Dmitri, Zhao, Luping, Wooldridge, James E., Krieg, Arthur M., Davar, Diwakar
Published in Journal of investigative dermatology (01.10.2022)
Published in Journal of investigative dermatology (01.10.2022)
Get full text
Journal Article
Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors
Powderly, John D., Sullivan, Ryan J., Gutierrez, Martin, Khattak, Adnan, Thomas, Sajeve Samuel, Jimeno, Antonio, Pascarella, Stephanie, Zhu, Lili, Morrissey, Manju, Meehan, Robert S., Barlaskar, Ferdous, Brown, Michelle, Spigel, David R.
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma
Panella, Timothy J., Thomas, Sajeve Samuel, McKean, Meredith, Margolin, Kim Allyson, Weight, Ryan Michael, Mani, Jayakumar, Patel, Shraddha, Desai, Priya, Salvati, Mark, Lowy, Israel, Fury, Matthew G., Gullo, Giuseppe
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors
Thomas, Sajeve Samuel, Pico, Brian, Henick, Brian S., Leidner, Rom, Samhouri, Yazan, Isaacs, James, Weiss, Jared, Hurwitz, Michael E., Grewal, Jaspreet Singh, Luke, Jason J., Chattopadhyay, Shrikanta, Wang, Yun, Motta, Marlyane, Murray, Jim, Barton, Debora, Pinchasik, Dawn, MacBeath, Gavin, Moser, Justin C
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A
Thomas, Sajeve Samuel, Gogas, Helen, Hong, Young Ki, In, Gino Kim, Doger de Spéville Uribe, Bernard, Furness, Andrew J.S., García Castaño, Almudena, Haefliger, Simon, He, Kai, Medina, Theresa, Lawrence, Donald, Lee, Sylvia, Martin-Liberal, Juan, Graf Finckenstein, Friedrich, Gastman, Brian, Chou, Jeffrey, Fiaz, Rana, Catlett, Melissa, Chen, Guang, Terheyden, Patrick
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article